These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37812926)

  • 1. Cellular Therapy in Chronic Lymphocytic Leukemia: Have We Advanced in the Last Decade?
    Katz OB; Yehudai-Ofir D; Zuckerman T
    Acta Haematol; 2024; 147(1):99-112. PubMed ID: 37812926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is There a Role for Cellular Therapy in Chronic Lymphocytic Leukemia?
    Dreger P
    Cancer J; 2021 Jul-Aug 01; 27(4):297-305. PubMed ID: 34398556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Antigen Receptor T Cells in Chronic Lymphocytic Leukemia: Are We Any Closer to a Cure?
    Rhodes JM; Schuster SJ
    Cancer J; 2019; 25(6):436-441. PubMed ID: 31764125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia.
    Bair SM; Porter DL
    Am J Hematol; 2019 May; 94(S1):S10-S17. PubMed ID: 30861173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular Therapy Advances in Chronic Lymphocytic Leukemia and Richter's Syndrome.
    Bajwa A; Voorhees TJ; Kittai AS
    Curr Probl Cancer; 2022 Feb; 46(1):100827. PubMed ID: 34991902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell therapy of chronic lymphocytic leukaemia: Transplants and chimeric antigen receptor (CAR)-T cells.
    Yang S; Huang X; Gale RP
    Blood Rev; 2022 Jan; 51():100884. PubMed ID: 34489116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells.
    Fraietta JA; Schwab RD; Maus MV
    Semin Oncol; 2016 Apr; 43(2):291-9. PubMed ID: 27040708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of chimeric antigen T-cell therapy in chronic lymphocytic leukemia.
    Siddiqi T
    Clin Adv Hematol Oncol; 2022 Jun; 20(6):366-368. PubMed ID: 35731607
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond.
    Shadman M; Maloney DG
    Hematol Oncol Clin North Am; 2021 Aug; 35(4):847-862. PubMed ID: 34174989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia.
    Kovalovsky D; Yoon JH; Cyr MG; Simon S; Voynova E; Rader C; Wiestner A; Alejo J; Pittaluga S; Gress RE
    Leukemia; 2021 Sep; 35(9):2581-2591. PubMed ID: 33633313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
    Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transforming CLL management with immunotherapy: Investigating the potential of CAR T-cells and bispecific antibodies.
    Borogovac A; Siddiqi T
    Semin Hematol; 2024 Apr; 61(2):119-130. PubMed ID: 38290860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned.
    Can I; Cox MJ; Siegler EL; Sakemura R; Kenderian SS
    Exp Hematol; 2022 Apr; 108():1-7. PubMed ID: 35150777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia.
    Zou Y; Xu W; Li J
    J Hematol Oncol; 2018 Nov; 11(1):130. PubMed ID: 30458878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into Chimeric Antigen Receptor Therapy for Chronic Lymphoblastic Leukemia.
    Hamieh M; Sadelain M
    Trends Mol Med; 2018 Sep; 24(9):729-731. PubMed ID: 30149852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia.
    Mancikova V; Smida M
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia.
    Cox MJ; Lucien F; Sakemura R; Boysen JC; Kim Y; Horvei P; Manriquez Roman C; Hansen MJ; Tapper EE; Siegler EL; Forsman C; Crotts SB; Schick KJ; Hefazi M; Ruff MW; Can I; Adada M; Bezerra E; Kankeu Fonkoua LA; Nevala WK; Braggio E; Ding W; Parikh SA; Kay NE; Kenderian SS
    Mol Ther; 2021 Apr; 29(4):1529-1540. PubMed ID: 33388419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
    Singh N; Frey NV; Grupp SA; Maude SL
    Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor T cells targeting Fc μ receptor selectively eliminate CLL cells while sparing healthy B cells.
    Faitschuk E; Hombach AA; Frenzel LP; Wendtner CM; Abken H
    Blood; 2016 Sep; 128(13):1711-22. PubMed ID: 27535994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy.
    Shadman M; Gauthier J; Hay KA; Voutsinas JM; Milano F; Li A; Hirayama AV; Sorror ML; Cherian S; Chen X; Cassaday RD; Till BG; Gopal AK; Sandmaier BM; Maloney DG; Turtle CJ
    Blood Adv; 2019 Oct; 3(20):3062-3069. PubMed ID: 31648329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.